octreotide acetate / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 141 Diseases   27 Trials   27 Trials   1501 News 


1234567891011»
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial completion date, Trial primary completion date, Metastases:  Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) -  Dec 18, 2024   
    P1,  N=14, Recruiting, 
    Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  Oclaiz (octreotide subcutaneous depot) / Camurus
    Trial completion date, Trial primary completion date:  SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET (clinicaltrials.gov) -  Dec 13, 2024   
    P3,  N=332, Active, not recruiting, 
    Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2024 --> Dec 2025 Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2025
  • ||||||||||  octreotide acetate / Generic mfg.
    68Ga-DOTATATE uptake in leiomyoma (e-Poster Area) -  Sep 27, 2024 - Abstract #EANM2024EANM_2682;    
    Although 68Ga-DOTATATE PET/CT scans are highly accurate for neuroendocrine tumors imaging, DOTATATE uptake could also be seen in various non-neuroendocrine conditions, including thymoma, prostatitis, and vertebral haemangioma. And in case of DOTATATE uptake in uterus, diagnosis of leiomyoma should also be considered.
  • ||||||||||  Review, Journal:  Medical treatment of acromegaly - When the tumor size matters: A narrative review. (Pubmed Central) -  Sep 15, 2024   
    Therefore, an individual approach is necessary in the treatment of patients with acromegaly, based on repeated insight to their clinical, biochemical, pathological and imaging characteristics. In this review, we summarize and comment how pituitary tumor size is affected by the treatment with all currently available drugs in acromegaly: long-acting somatostatin receptor ligands of the first generation (octreotide LAR and lanreotide autogel) and the second generation (pasireotide-LAR), as well as pegvisomant (PEG) and cabergoline (CAB).
  • ||||||||||  octreotide acetate / Generic mfg.
    Small But Not Silent: A Case of Small Bowel Neuroendocrine Tumor Induced Small Bowel Obstruction (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_3783;    
    1 The increasing incidence of NET, with SBNETs emerging as clinically important and must not miss diagnosis, has driven significant advances in therapeutic options including Lu-DOTATATE to improve progression-free survival. 4 Figure: Distal 2.5 cm Small Bowel Neuroendocrine Tumor inducing Small Bowel Obstruction.
  • ||||||||||  octreotide acetate / Generic mfg.
    Persistent Thrombocytopenia Following Long-Acting Octreotide Therapy in Angioectasia: A Case Report (Exhibit Hall E) -  Aug 20, 2024 - Abstract #ACG2024ACG_2995;    
    In conclusion, our case highlights a rare instance of persistent thrombocytopenia following long-acting octreotide therapy in angioectasia and underscores the challenge of managing recurrent GI bleeding in such cases. Note: The table for this abstract can be viewed in the ePoster Gallery section of the ACG 2024 ePoster Site or in The American Journal of Gastroenterology's abstract supplement issue, both of which will be available starting October 27, 2024.
  • ||||||||||  prednisone / Generic mfg., azithromycin / Generic mfg., octreotide acetate / Generic mfg.
    A RARE CAUSE OF COUGH AND WHEEZING: A CASE OF DIFFUSE IDIOPATHIC PULMONARY NEUROENDOCRINE CELL HYPERPLASIA IN A YOUNG WOMAN (Convention Center Exhibit Hall: Poster Area 2) -  Jul 31, 2024 - Abstract #CHEST2024CHEST_2770;    
    In routine practice, many cases of chronic cough, wheezing, and shortness of breath are often a result of asthma, chronic obstructive pulmonary disease, or reactive airway disease. However, on rare occasions, this will not be the diagnosis, requiring the clinician to think outside the box, putting together all aspects of the clinical evaluation to formulate a differential diagnosis, try empiric therapy, and conduct further investigation that will unravel the diagnosis.
  • ||||||||||  octreotide acetate / Generic mfg.
    Trial completion:  Effects of Sandostatin LAR (clinicaltrials.gov) -  Jul 24, 2024   
    P4,  N=21, Completed, 
    However, on rare occasions, this will not be the diagnosis, requiring the clinician to think outside the box, putting together all aspects of the clinical evaluation to formulate a differential diagnosis, try empiric therapy, and conduct further investigation that will unravel the diagnosis. Unknown status --> Completed
  • ||||||||||  temozolomide / Generic mfg., octreotide acetate / Generic mfg.
    Journal:  Treatment of an Aggressive Gonadotroph Pituitary Neuroendocrine Tumor With 177Lutetium DOTATATE Radionuclide Therapy. (Pubmed Central) -  Jul 16, 2024   
    Chemotherapy, particularly temozolomide, is often pursued for tumors that progress despite these treatments...At age 56, further tumor regrowth and a positive octreotide scan prompted treatment with long-acting octreotide for 1 year...This is only the second report on the effectiveness of PRRT in patients with aggressive gonadotroph PitNETs. We also provide an overview of PRRT for PitNETs and describe clinical outcomes previously reported in the literature.
  • ||||||||||  Lutathera (lutetium Lu 177 dotatate) / Novartis
    New P2 trial:  LUMEN-1: 177Lu-DOTATATE for Recurrent Meningioma (clinicaltrials.gov) -  Mar 22, 2024   
    P2,  N=135, Not yet recruiting, 
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    SPECTRUM OF PANCREATIC NEUROENDOCRINE TUMOURS (PNETS) IN INDIAN PATIENTS WITH MEN1 SYNDROME () -  Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_1049;    
    PNETs occur frequently in Indian MEN1 patients, majority are non-functioning, are often multifocal and overt malignancy with metastatic disease is not uncommon. Resection is commonly required for functional PNETs Abbreviations: PD-pancreatoduodenectomy, TP-total pancreatectomy, DP-distal pancreatectomy, Enucleation, FU-Follow-up, SACST- Selective arterial calcium stimulation test
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    CHALLENGING ABNORMAL THYROID FUNCTION TESTS; TSHOMA: A CASE REPORT () -  Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_720;    
    -TSHoma though very rare pituitary tumor, however, it does exist. -Difficult to differentiate between TSHoma and Resistance to thyroid hormone in resource limited developing countries.
  • ||||||||||  octreotide subcutaneous depot (CAM2029) / Camurus
    A RANDOMIZED PHASE 3 TRIAL TO ASSESS EFFICACY AND SAFETY OF A NOVEL FORMULATION OF OCTREOTIDE SUBCUTANEOUS DEPOT IN PATIENTS WITH ACROMEGALY (Umm Al Quwain hall) -  Mar 17, 2024 - Abstract #ICEEDEC2024ICE_EDEC_595;    
    P3
    In this phase 3, multinational, randomized, double-blind, placebo-controlled trial (NCT04076462), patients on stable treatment with octreotide LAR or lanreotide autogel, and with normal IGF-1 levels at screening, were randomized 2:1 to once-monthly CAM2029 20 mg or placebo for 24 weeks. CAM2029 treatment resulted in robust biochemical control superior to placebo, substantially improved PROs compared to baseline SoC and placebo, and a safety profile consistent with SoC somatostatin receptor ligand treatments, demonstrating the potential of CAM2029 as an alternative to SoC acromegaly treatments that addresses unmet patient needs.
  • ||||||||||  octreotide acetate / Generic mfg.
    COST-EFFECTIVENESS OF MONTHLY LONG-ACTING OCTREOTIDE INJECTIONS IN PREVENTING SMALL BOWEL BLEEDING FROM ARTERIOVENOUS MALFORMATIONS (Hall A, Poster Hall - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_6915;    
    Conclusion For patients with recurrent small bowel bleeding from AVMs, monthly, long-acting octreotide injections are cost-effective in preventing further bleeding events and their associated morbidity. Our findings may be used to guide decision-making surrounding insurance coverage of long-acting octreotide injections for patients with small bowel AVMs.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Enrollment open, Metastases:  ADPKD648: Outcome of ADPKD With Octreotide LAR (clinicaltrials.gov) -  Mar 14, 2024   
    P=N/A,  N=70, Recruiting, 
    Our findings may be used to guide decision-making surrounding insurance coverage of long-acting octreotide injections for patients with small bowel AVMs. Not yet recruiting --> Recruiting
  • ||||||||||  Lutathera (lutetium Lu 177 dotatate) / Novartis, Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Sequencing of Somatostatin-Receptor-Based Therapies in Neuroendocrine Tumor Patients. (Pubmed Central) -  Mar 4, 2024   
    This question is particularly complicated given the heterogeneity of NETs and the near absence of randomized trials comparing active treatment options. This state-of-the-art review examines the evidence supporting use of somatostatin-receptor-targeted treatments within the larger landscape of NET therapy and offers insights regarding optimal patient selection, assessment of benefit versus risk, and treatment sequencing.
  • ||||||||||  Oclaiz (octreotide subcutaneous depot) / Camurus
    Enrollment closed:  SORENTO: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients with GEP-NET (clinicaltrials.gov) -  Jan 25, 2024   
    P3,  N=332, Active, not recruiting, 
    This state-of-the-art review examines the evidence supporting use of somatostatin-receptor-targeted treatments within the larger landscape of NET therapy and offers insights regarding optimal patient selection, assessment of benefit versus risk, and treatment sequencing. Recruiting --> Active, not recruiting
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Journal:  Proton-pump inhibitor-induced bone loss is preventable by concomitant use of a long-acting somatostatin analogue. (Pubmed Central) -  Jan 18, 2024   
    There was no significant difference in the serum levels of gastrin, PTH, ALP, and also BMD in the rats that received sandostatin+ pantoprazole or sandostatin alone, compared to the control group. This study showed that the pantoprazole-induced bone loss, through elevation of serum gastrin and PTH, was preventable by concomitant use of a long-acting somatostatin analog.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    Incidental Finding Of Small Isntestinal NET During Explomatory Laparatomy For Ovarian Cancer. (Poster area) -  Jan 18, 2024 - Abstract #ESGO2024ESGO_1133;    
    Multidisciplinary team decided that adjuvant therapy with octreotide lar was necessary...Mesenteric lymph node metastases are present in more than 80% of patients at diagnosis, regardless of the size of the primary tumor. We bring into attention the possible incidental finding of NET tumors during exploratory laparotomy for gynecological conditions.
  • ||||||||||  Sandostatin LAR Depot (octreotide acetate) / Novartis
    New trial, Metastases:  ADPKD648: Outcome of ADPKD With Octreotide LAR (clinicaltrials.gov) -  Jan 4, 2024   
    P=N/A,  N=70, Not yet recruiting, 
  • ||||||||||  Leukine (sargramostim) / Partner Therap, SurVaxM (SVN53-67/M57-KLH peptide vaccine) / MimiVax
    Trial completion date, Trial primary completion date, Metastases:  Survivin Long Peptide Vaccine in Treating Patients With Metastatic Neuroendocrine Tumors (clinicaltrials.gov) -  Dec 29, 2023   
    P1,  N=14, Recruiting, 
    Octreotide effectively reduces transfusion requirements and the need for endoscopic therapy in patients with angiodysplasia-related anemia. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Dec 2024